BiotechTube

OSE-127 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

Oct 2, 2020 → Jan 28, 2025

NCT ID
NCT04882007

About OSE-127 + Placebo

OSE-127 + Placebo is a phase 2 stage product being developed by OSE Immunotherapeutics for Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04882007. Target conditions include Ulcerative Colitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04882007Phase 2Completed

Competing Products

20 competing products in Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
77
MirikizumabEli LillyPhase 2
52
Azathioprine + PlaceboCelltrionApproved
85
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
TacrolimusAstellas PharmaPhase 3
77
tacrolimus + PlaceboAstellas PharmaPhase 3
77
Filgotinib MaleateEisaiApproved
85
AJM300 + PlaceboEisaiPhase 3
77
GSK3050002 + PlaceboEisaiPhase 1
33
adalimumab + placeboEisaiPhase 3
77
E6007 + PlaceboEisaiPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 1
33
Arm1 + Arm 2Zydus LifesciencesPhase 2
52
Mirikizumab + MirikizumabEli LillyPhase 3
77
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 2
52
Mirikizumab + PlaceboEli LillyPhase 2
52
LY4268989 + PlaceboEli LillyPhase 2
52

Other Products from OSE Immunotherapeutics

OSE2101 + DocetaxelPhase 3
69
OSE2101 + Docetaxel + PemetrexedPhase 3
69
FOLFIRI + OSE2101Phase 2
44
FR104Phase 1/2
33
Part A: OSE-279 100mg + Part A: OSE-279 300mg + Part A: OSE-279 600mg + Part B: OSE-279 600 mg and OSE2101 + Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive + Part C: OSE-279 600 mg - HLA-A2 positif + Part C: OSE-279 600 mg - HLA-A2 negativePhase 1/2
33